Brett Stanaland, MD
Allergy · Naples, FLNPI 1508865924
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $500,684 of the $575,255 with a category attached, or 87.0%. 36 manufacturers reported payments, led by GSK at 57.6% of the total. Reporting peaked in 2024 at $195,588 and has fallen 52.6% since, to $92,700 in 2025. Among allergy clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 865 payments — averaging $665.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$331K
- AstraZeneca$215K
- Incyte Corporation$11K
- Regeneron Healthcare Solutions, Inc.$8K
- Amgen$3K
- Optinose US, Inc.$2K
- plus $6K from 30 others
What the payments were for
- Speaking & faculty fees$500,68487%
- Travel & lodging$51,4989%
- Food & beverage$22,9584%
- Education$1150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 321 | $331,116 |
| AstraZeneca | 239 | $214,638 |
| Incyte Corporation | 20 | $11,288 |
| Regeneron Healthcare Solutions, Inc. | 40 | $8,052 |
| Amgen(2 entities) | 12 | $2,533 |
| Optinose US, Inc. | 9 | $1,934 |
| Sanofi | 36 | $1,022 |
| Takeda Pharmaceuticals U.S.A., Inc. | 25 | $681 |
| Genentech USA, Inc. | 17 | $562 |
| CSL Behring | 19 | $484 |
| Grifols USA, LLC | 21 | $439 |
| Pfizer | 19 | $350 |
| Novartis | 17 | $319 |
| Covis Pharma GmbH | 14 | $291 |
| Kaleo, Inc. | 13 | $196 |
| Biocryst US Sales Co., LLC | 5 | $167 |
| ADMA Biomanufacturing LLC | 1 | $150 |
| Blueprint Medicines Corporation | 1 | $126 |
| Regeneron | 1 | $121 |
| Sanofi-aventis U.S. LLC | 2 | $121 |
| AbbVie | 5 | $115 |
| Shire North American Group Inc | 5 | $93 |
| Sunovion Pharmaceuticals Inc. | 5 | $88 |
| Teva Pharmaceuticals USA, Inc. | 4 | $84 |
| Pharming Healthcare, Inc. | 2 | $45 |
| Insmed, Inc. | 2 | $43 |
| Azurity Pharmaceuticals, Inc. | 1 | $28 |
| Boehringer Ingelheim | 1 | $25 |
| Bristol Myers Squibb | 1 | $24 |
| LEO Pharma Inc. | 1 | $19 |
| Mylan Specialty L.p. | 1 | $19 |
| Alk-abello, Inc | 1 | $18 |
| Verona Pharma, Inc. | 1 | $17 |
| Hikma Pharmaceuticals USA | 1 | $17 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
| Phadia US Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$575,255 in reported general payments places this provider in the 95th percentile of 56 allergy providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HaegardaC1 Esterase Inhibitor | 17 | $537,025 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 405 | $334,300 |
| Breo ElliptaFluticasone/Vilanterol | 134 | $87,797 |
| RinvoqUpadacitinib | 12 | $83,611 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 67 | $50,624 |
| XolairOmalizumab | 17 | $47,525 |
| Dupixent SyringeDupilumab | 11 | $39,934 |
| Azelastine Hcl | 842 | $32,289 |
| Arnuity ElliptaFluticasone Furoate | 59 | $23,314 |
| Spiriva RespimatTiotropium Bromide | 30 | $21,658 |
| Epinephrine | 88 | $16,458 |
| Ipratropium Bromide | 332 | $16,023 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 63 | $10,496 |
| SymbicortBudesonide/Formoterol Fumarate | 27 | $10,361 |
| Qvar RedihalerBeclomethasone Dipropionate | 22 | $8,791 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringHaegarda | $484 | $537,02517 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $331,116 | $445,411598 claims |
| AbbVieRinvoq | $115 | $83,61112 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $214,638 | $60,98594 claims |
| Boehringer IngelheimSpiriva Respimat | $25 | $21,65830 claims |
| Hikma Pharmaceuticals USAEpinephrine | $17 | $16,45888 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $84 | $8,79122 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 56 allergy providers in Florida.
Other allergy in Naples
- Miguel LanzCoral Gables$778K
- David RoseEglin Afb$253K
- Pavana BeerelliRockledge$61K
- Hugh WindomSarasota$37K
- Patrick de MarcoOrange Park$23K
- Mark MinorMelbourne$21K
- Alan KoterbaNorth Palm Beach$16K
- Brian WilsonTallahassee$11K
- Sanjay SwamiJacksonville$11K
- Latha ChamarthyPinellas Park$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.